Secondary cytokine production by lymphoid cells used in cellular immunotherapy
- 30 April 1992
- journal article
- research article
- Published by Elsevier in Surgical Oncology
- Vol. 1 (2) , 163-172
- https://doi.org/10.1016/0960-7404(92)90030-o
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinomaThe Lancet, 1990
- Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humansCancer Immunology, Immunotherapy, 1989
- Use of anti-HLA antibodies to mask major histocompatibility complex gene products on tumor cells can enhance susceptibility of these cells to lysis by natural killer cells.Journal of Clinical Investigation, 1989
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsNew England Journal of Medicine, 1988
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategyNature, 1986
- Interleukin 2 Regulates Expression of Its Receptor and Synthesis of Gamma Interferon by Human T LymphocytesScience, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu miceNature, 1980
- Long term culture of tumour-specific cytotoxic T cellsNature, 1977